汇宇制药：卡络磺钠注射液获药品注册证书

Core Viewpoint - The company has received approval from the National Medical Products Administration for the marketing of its drug, Caroverine Sodium Injection, which is indicated for various bleeding disorders [1] Group 1: Product Approval - The company's wholly-owned subsidiary, Sichuan Huiyu Haiyue Pharmaceutical Technology Co., Ltd., has been granted a drug registration certificate for Caroverine Sodium Injection [1] - Caroverine Sodium Injection is designed to reduce capillary permeability, enhance the retraction of capillary rupture ends, and increase resistance to damage, thereby shortening bleeding time without affecting blood coagulation and fibrinolysis [1] Group 2: Market Potential - The drug is applicable for bleeding diseases in the urinary system, upper digestive tract, respiratory tract, and obstetrics and gynecology [1] - The projected sales revenue for Caroverine Sodium Injection in urban public hospitals in China for 2024 is estimated to be 3.39 million yuan [1] - The company has initiated preparatory work for the product's market launch and sales [1]